Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), ...

Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC

Verastem, Inc. shifts focus to VS-7375 for KRAS G12D tumors after ending RAMP-203. Click to learn about VSTM's key catalysts ...

FDA approves Jascayd for progressive pulmonary fibrosis

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary ...
The Blogs | The Times of Israel

Restoring Metabolic Balance to Fight Cancer

The extreme weight loss seen in many late-stage cancer patients, known as cachexia, is far more than a cosmetic side effect.